Legal & General Group
NMRA icon

Legal & General Group’s Neumora Therapeutics NMRA Stock Holding History

Legal & General Group’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17K Buy
+9,971
New +$19K ﹤0.01% 3190
2025
Q2 		– Sell
-10,500
Closed -$10.5K – 3493
2025
Q1 		$10.5K Sell
10,500
-49,342
-82% -$84.5K ﹤0.01% 3161
2024
Q4 		$634K Buy
59,842
+50,289
+526% +$603K ﹤0.01% 2376
2024
Q3 		$126K Buy
9,553
+249
+3% +$2.9K ﹤0.01% 2715
2024
Q2 		$91.4K Buy
9,304
+7,882
+554% +$81.6K ﹤0.01% 2734
2024
Q1 		$19.5K Hold
1,422
– – ﹤0.01% 2971
2023
Q4 		$24.2K Sell
1,422
-8,578
-86% -$105K ﹤0.01% 2955
2023
Q3 		$140K Buy
+10,000
New +$125K ﹤0.01% 2786

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Legal & General Group's NMRA Position: Q2 2026 in Review

Legal & General Group opened a new position in Neumora Therapeutics (NMRA) in Q2 2026: 9,971 shares worth $17K. The stake represents ﹤0.01% of the portfolio and ranks #3190 among its holdings. This is a return to the name: Legal & General Group previously reported a position in NMRA as recently as Q1 2025.

Legal & General Group first reported a position in NMRA in Q3 2023 and has held it in 8 quarters since. The position peaked at $634K in Q4 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Legal & General Group held 9,971 shares of Neumora Therapeutics worth $17K as of Q2 2026.
  • Neumora Therapeutics was a new Legal & General Group position in Q2 2026.
  • Neumora Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3190 holding.
  • Legal & General Group first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 8 quarters since.
  • Legal & General Group's Neumora Therapeutics position peaked at $634K in Q4 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.